Search results for "4-Methylpyridine"

showing 10 items of 18 documents

One-dimensional oxalato-bridged copper(II) complexes with 3-hydroxypyridine and 2-amino-4-methylpyridine

2001

Two new one-dimensional oxalato-bridged copper(II) compounds of formula [Cu(ox)L2]n (1) and {[Cu2(ox)2L%3]·L%}n (2) [ox oxalate dianion, L3-hydroxypyridine (pyOH) and L% 2-amino-4-methylpyridine (ampy)] have been synthesized and characterized by FT-IR spectroscopy, variable-temperature magnetic measurements and single-crystal X-ray diffraction. The crystal structure of 1 comprises chains of copper atoms in which cis-[Cu(pyOH)2] 2 units are sequentially bridged by asymmetric bis-bidentate oxalato ligands with an intrachain copper‐copper separation of 5.548(1) A, . Each copper atom is six-coordinated: four oxygen atoms belonging to two bridging oxalato ligands and two nitrogen atoms from two …

Chemistrychemistry.chemical_elementCrystal structureCopperMagnetic susceptibilitySquare pyramidal molecular geometryOxalateInorganic ChemistryCrystallographychemistry.chemical_compoundOctahedron4-MethylpyridineMaterials ChemistryPhysical and Theoretical ChemistryCoordination geometryInorganica Chimica Acta
researchProduct

New Hypolipaemic Agents Designed by Molecular Topology: Pharmacological Studies of 2,6-Di-tert-butyl-4-methylpyridine and 2,6-Di-tert-butylpyridine

1999

New compounds showing hypolipaemic activity have been designed using a computer-aided method based on molecular topology and QSAR analysis. Linear discriminant analysis and connectivity functions were used to design three potentially suitable drugs which were tested for hypolipaemic properties by the Triton WR-1339 test in rats. The pharmacological tests carried out on the newly designed compounds demonstrated the existence of notable activity in phase I for two of them. namely 2,6-Di-tert-butyl-4-methylpyridine (C.A.S. 38222-83-2) and 2,6-Di-tert-butylpyridine (C.A.S. 585-48-8), with respect to the level of total cholesterol. Both substances decrease the lipaemia to lower levels than clofi…

PharmacologyTert butylQuantitative structure–activity relationshipClofibrateChemistryStereochemistry26-Di-tert-butylpyridineReference drugchemistry.chemical_compoundTotal cholesterol4-MethylpyridinemedicineMolecular topologymedicine.drugQuantitative Structure-Activity Relationships
researchProduct

CCDC 1441504: Experimental Crystal Structure Determination

2018

Related Article: Michael G. S. Londesborough, Jiří Dolanský, Tomáš Jelínek, John D. Kennedy, Ivana Císařová, Robert D. Kennedy, Daniel Roca-Sanjuán, Antonio Francés-Monerris, Kamil Lang, William Clegg|2018|Dalton Trans.|47|1709|doi:10.1039/C7DT03823B

Space GroupCrystallography5'6':56-conjuncto-(3'8'-bis(4-methylpyridine-N)-4'5':6'7'-di-muH-arachno-octaborane)-(89:910-di-muH-nido-decaborane)Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1450584: Experimental Crystal Structure Determination

2016

Related Article: Rakesh Puttreddy, Ngong Kodiah Beyeh, Kari Rissanen|2016|CrystEngComm|18|4971|doi:10.1039/C6CE00240D

Space GroupCrystallographyCrystal SystemC-Methylcalix(4)resorcinarene bis(4-methylpyridine N-oxide) clathrate methanol solvateCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1935931: Experimental Crystal Structure Determination

2020

Related Article: Rakesh Puttreddy, J. Mikko Rautiainen, Toni Mäkelä, Kari Rissanen|2019|Angew.Chem.,Int.Ed.|58|18610|doi:10.1002/anie.201909759

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters1H-1lambda62-benzothiazole-113(2H)-trione 4-methylpyridine N-oxideExperimental 3D Coordinates
researchProduct

CCDC 1557847: Experimental Crystal Structure Determination

2017

Related Article: Filip Topić, Rakesh Puttreddy, J. Mikko Rautiainen, Heikki M. Tuononen, Kari Rissanen|2017|CrystEngComm|19|4960|doi:10.1039/C7CE01381G

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters4-methylpyridine N-oxideExperimental 3D Coordinates
researchProduct

CCDC 1837605: Experimental Crystal Structure Determination

2019

Related Article: Rakesh Puttreddy, Ngong Kodiah Beyeh, S Maryamdokht Taimoory, Daniel Meister, John F Trant, Kari Rissanen|2018|Beilstein J.Org.Chem.|14|1723|doi:10.3762/bjoc.14.146

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters5111723-tetrabromo-281420-tetrahexylpentacyclo[19.3.1.137.1913.11519]octacosa-1(25)3(28)469(27)101215(26)16182123-dodecaene-46101216182224-octol 4-methylpyridine-N-oxide methanol solvateExperimental 3D Coordinates
researchProduct

CCDC 1551405: Experimental Crystal Structure Determination

2017

Related Article: Rakesh Puttreddy, Ngong Kodiah Beyeh, Robin H. A. Ras, John F. Trant, Kari Rissanen|2017|CrystEngComm|19|4312|doi:10.1039/C7CE00975E

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersC-ethyl-2-bromoresorcinarene tris(4-methylpyridine N-oxide)Experimental 3D Coordinates
researchProduct

CCDC 1557843: Experimental Crystal Structure Determination

2017

Related Article: Filip Topić, Rakesh Puttreddy, J. Mikko Rautiainen, Heikki M. Tuononen, Kari Rissanen|2017|CrystEngComm|19|4960|doi:10.1039/C7CE01381G

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates4-methylpyridine-N-oxide bis(1122-tetrafluoro-12-di-iodoethane)
researchProduct

CCDC 986178: Experimental Crystal Structure Determination

2014

Related Article: Georg Meyer-Eppler, Filip Topić, Gregor Schnakenburg, Kari Rissanen, Arne Lützen|2014|Eur.J.Inorg.Chem.||2495|doi:10.1002/ejic.201402057

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(22'-(tricyclo[8.2.2.2^47^]hexadeca-1(12)46101315-hexaene-511-diyldiethyne-21-diyl)bis(4-methylpyridine))-palladium(ii) bis(22'-(tricyclo[8.2.2.2^47^]hexadeca-1(12)46101315-hexaene-511-diyldiethyne-21-diyl)bispyridine)-palladium(ii) tetrakis(tetrafluoroborate)Experimental 3D Coordinates
researchProduct